We are analyzing https://link.springer.com/article/10.1007/s00262-014-1607-y.

Title:
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease | Cancer Immunology, Immunotherapy
Description:
Two patients were treated with immunotherapy for metastatic malignant melanoma (MM) despite suffering from systemic autoimmune disease, i.e., ulcerative colitis (UC) and Behcets disease (BD), respectively. Both patients benefitted from the treatment. The patient with UC achieved partial remission of all measurable parameters after treatment with Ipilimumab, while the patient with BD achieved a complete remission of MM after treatment with Interleukin-2 (IL-2) and Interferon-α (IFN-α). Moreover, no aggravation of symptoms related to the autoimmune diseases was seen during treatment, in contrast, clinical indications of improvement were observed. These two cases illustrate that the presence of autoimmune disease does not necessarily predict increased autoimmune toxicity in connection with immunotherapy. They also raise the question of whether autoimmune disease should continue to be an absolute exclusion criterion for treatment of MM with immunotherapy. Consequently, given the poor prognosis of refractory MM, immunotherapies need to be taken into consideration even in cases of autoimmune comorbidity due to the potential long-term benefit that these therapies offer to MM patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

article, pubmed, google, scholar, cas, melanoma, cancer, treatment, patients, disease, immunotherapy, autoimmune, interleukin, ipilimumab, metastatic, herlev, central, behcets, access, clin, therapy, immunol, copenhagen, privacy, cookies, content, nat, rev, schadendorf, cells, department, hospital, university, denmark, publish, search, systemic, pedersen, andersen, peter, inge, marie, svane, ulcerative, colitis, diseases, regulatory, oncol, hauschild, data,

Topics {✒️}

type-ii-interferon-mediated signalling month download article/chapter article cancer immunology inge marie svane t-cell transfer immunotherapy anti-ctla-4 therapy potential long-term benefit functional cd4 + cd25high regulatory systemic autoimmune disease cancer immune therapy stage iv melanoma—safety interferon alpha-2a therapy full article pdf autoimmune diseases phase ii trials tumour immunotherapy cancer consensus statement metastatic malignant melanoma immune regulatory antibodies autoimmune comorbidity due privacy choices/manage cookies therapies offer van bodegraven aa distant metastatic disease article pedersen melan-a-specific interferon-gamma-producing european economic area absolute exclusion criterion hodi fs rare side effects cell-extrinsic regulator infectious diseases autoimmune toxicity autoimmune disease conditions privacy policy cancer therapy active ulcerative colitis article log de boer nk ctla4 check access sherry rm instant access cancer immunotherapy accepting optional cookies durable complete responses updated british society gastroenterology reporting guidelines regulatory cell function

Questions {❓}

Wolchok JD, Yang AS, Weber JS (2010) Immune regulatory antibodies: are they the next advance?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
         description: Two patients were treated with immunotherapy for metastatic malignant melanoma (MM) despite suffering from systemic autoimmune disease, i.e., ulcerative colitis (UC) and Behcets disease (BD), respectively. Both patients benefitted from the treatment. The patient with UC achieved partial remission of all measurable parameters after treatment with Ipilimumab, while the patient with BD achieved a complete remission of MM after treatment with Interleukin-2 (IL-2) and Interferon-α (IFN-α). Moreover, no aggravation of symptoms related to the autoimmune diseases was seen during treatment, in contrast, clinical indications of improvement were observed. These two cases illustrate that the presence of autoimmune disease does not necessarily predict increased autoimmune toxicity in connection with immunotherapy. They also raise the question of whether autoimmune disease should continue to be an absolute exclusion criterion for treatment of MM with immunotherapy. Consequently, given the poor prognosis of refractory MM, immunotherapies need to be taken into consideration even in cases of autoimmune comorbidity due to the potential long-term benefit that these therapies offer to MM patients.
         datePublished:2014-09-17T00:00:00Z
         dateModified:2014-09-17T00:00:00Z
         pageStart:1341
         pageEnd:1346
         sameAs:https://doi.org/10.1007/s00262-014-1607-y
         keywords:
            Metastatic malignant melanoma
            Immune therapy
            Systemic autoimmune disease
            Ipilimumab
            Interleukin-2
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-014-1607-y/MediaObjects/262_2014_1607_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-014-1607-y/MediaObjects/262_2014_1607_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-014-1607-y/MediaObjects/262_2014_1607_Fig3_HTML.jpg
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:63
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Magnus Pedersen
               affiliation:
                     name:Herlev Hospital, University of Copenhagen
                     address:
                        name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
                     name:University of Copenhagen
                     address:
                        name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rikke Andersen
               affiliation:
                     name:Herlev Hospital, University of Copenhagen
                     address:
                        name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
                     name:University of Copenhagen
                     address:
                        name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Nørgaard
               affiliation:
                     name:University of Copenhagen
                     address:
                        name:Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Søren Jacobsen
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Thielsen
               affiliation:
                     name:University of Copenhagen
                     address:
                        name:Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Per thor Straten
               affiliation:
                     name:Herlev Hospital, University of Copenhagen
                     address:
                        name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Inge Marie Svane
               affiliation:
                     name:Herlev Hospital, University of Copenhagen
                     address:
                        name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
                     name:University of Copenhagen
                     address:
                        name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
      description: Two patients were treated with immunotherapy for metastatic malignant melanoma (MM) despite suffering from systemic autoimmune disease, i.e., ulcerative colitis (UC) and Behcets disease (BD), respectively. Both patients benefitted from the treatment. The patient with UC achieved partial remission of all measurable parameters after treatment with Ipilimumab, while the patient with BD achieved a complete remission of MM after treatment with Interleukin-2 (IL-2) and Interferon-α (IFN-α). Moreover, no aggravation of symptoms related to the autoimmune diseases was seen during treatment, in contrast, clinical indications of improvement were observed. These two cases illustrate that the presence of autoimmune disease does not necessarily predict increased autoimmune toxicity in connection with immunotherapy. They also raise the question of whether autoimmune disease should continue to be an absolute exclusion criterion for treatment of MM with immunotherapy. Consequently, given the poor prognosis of refractory MM, immunotherapies need to be taken into consideration even in cases of autoimmune comorbidity due to the potential long-term benefit that these therapies offer to MM patients.
      datePublished:2014-09-17T00:00:00Z
      dateModified:2014-09-17T00:00:00Z
      pageStart:1341
      pageEnd:1346
      sameAs:https://doi.org/10.1007/s00262-014-1607-y
      keywords:
         Metastatic malignant melanoma
         Immune therapy
         Systemic autoimmune disease
         Ipilimumab
         Interleukin-2
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-014-1607-y/MediaObjects/262_2014_1607_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-014-1607-y/MediaObjects/262_2014_1607_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-014-1607-y/MediaObjects/262_2014_1607_Fig3_HTML.jpg
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:63
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Magnus Pedersen
            affiliation:
                  name:Herlev Hospital, University of Copenhagen
                  address:
                     name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
                  name:University of Copenhagen
                  address:
                     name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rikke Andersen
            affiliation:
                  name:Herlev Hospital, University of Copenhagen
                  address:
                     name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
                  name:University of Copenhagen
                  address:
                     name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Nørgaard
            affiliation:
                  name:University of Copenhagen
                  address:
                     name:Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Søren Jacobsen
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Thielsen
            affiliation:
                  name:University of Copenhagen
                  address:
                     name:Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Per thor Straten
            affiliation:
                  name:Herlev Hospital, University of Copenhagen
                  address:
                     name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Inge Marie Svane
            affiliation:
                  name:Herlev Hospital, University of Copenhagen
                  address:
                     name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
                  name:University of Copenhagen
                  address:
                     name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:63
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Herlev Hospital, University of Copenhagen
      address:
         name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital, University of Copenhagen
      address:
         name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital, University of Copenhagen
      address:
         name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital, University of Copenhagen
      address:
         name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Magnus Pedersen
      affiliation:
            name:Herlev Hospital, University of Copenhagen
            address:
               name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
            name:University of Copenhagen
            address:
               name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Rikke Andersen
      affiliation:
            name:Herlev Hospital, University of Copenhagen
            address:
               name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
            name:University of Copenhagen
            address:
               name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Peter Nørgaard
      affiliation:
            name:University of Copenhagen
            address:
               name:Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Søren Jacobsen
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Peter Thielsen
      affiliation:
            name:University of Copenhagen
            address:
               name:Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Per thor Straten
      affiliation:
            name:Herlev Hospital, University of Copenhagen
            address:
               name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Inge Marie Svane
      affiliation:
            name:Herlev Hospital, University of Copenhagen
            address:
               name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
            name:University of Copenhagen
            address:
               name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
      name:Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Haematology and Oncology, Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Herlev, Denmark
      name:Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(116)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.05s.

LINK . SPRINGER . COM {}